ATS-9R: Targeted Non-Viral Gene Delivery to White Adipose Tissue

Executive Summary: ATS-9R (Adipocyte-targeting sequence-9-arginine; C8721) is a non-viral gene delivery fusion oligopeptide designed for selective targeting of white adipose tissue by binding to Prohibitin on mature adipocytes and adipose tissue macrophages (Won et al., 2014). The nona-arginine motif (9R) enhances nucleic acid condensation, resulting in nanoparticle formation and efficient cellular uptake (Fig. 2a). ATS-9R-mediated complexes achieve 30–70% target gene knockdown with minimal cytotoxicity and liver clearance within 12–24 hours (Table 1). This platform offers robust gene silencing for adipocyte-specific research, including obesity, insulin resistance, and gestational diabetes mellitus (GDM) (APExBIO product page). Benchmarks and safety data distinguish ATS-9R from traditional viral vectors or non-targeted carriers (see related resource).

Biological Rationale

Obesity and its related metabolic disorders—such as type 2 diabetes and gestational diabetes mellitus (GDM)—are driven in part by excess lipid storage and chronic inflammation in white adipose tissue (WAT) (Won et al., 2014). White adipocytes store triglycerides and secrete pro-inflammatory cytokines. Adipose tissue macrophages (ATMs) contribute to local inflammation and insulin resistance. Targeting these cell populations is central to next-generation anti-obesity and metabolic disease therapies (APExBIO). Prohibitin, a membrane protein highly expressed in mature adipocytes and ATMs, serves as a selective molecular address for delivery systems. Traditional pharmacological agents often lack tissue selectivity, resulting in off-target effects and limited efficacy (Introduction). Non-viral gene therapy offers a safer alternative to viral vectors for transient, controlled gene silencing in adipose tissues.

Mechanism of Action of ATS-9R (Adipocyte-targeting sequence-9-arginine)

ATS-9R is a 17-residue fusion oligopeptide (Cys-Lys-Gly-Gly-Arg-Ala-Lys-Asp-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Cys) incorporating an adipocyte-targeting sequence (ATS: CKGGRAKDC) and nine consecutive arginine residues (9R). The ATS motif binds specifically to Prohibitin on the plasma membrane of mature white adipocytes and ATMs (Fig. 1). Upon binding, the complex is internalized by Prohibitin-mediated endocytosis. The 9R sequence facilitates strong electrostatic interaction with nucleic acids (shRNA, sgRNA/Cas9, etc.), enabling efficient condensation into nanoparticles (150–354 nm diameter; zeta potential 7–20 mV) (Methods). These particles are readily taken up by target cells, where the nucleic acid cargo is released intracellularly to mediate gene silencing. The process is non-viral, yielding transient expression and minimal immunogenicity. Clearance occurs predominantly through the liver within 12–24 hours post-injection.

Evidence & Benchmarks

• ATS-9R selectively accumulates in visceral (epiWAT) and subcutaneous (subWAT) white adipose tissue, with minimal hepatic distribution after systemic administration (Won et al., 2014, DOI).
• Complexes of ATS-9R and nucleic acids (weight ratio 3:1 or 6:1) form nanoparticles sized 150–354 nm and zeta potential 7–20 mV, as confirmed by dynamic light scattering and zeta analysis (Won et al., 2014, DOI).
• Gene silencing efficiency in vivo reaches 30–70% mRNA knockdown of targets such as FABP4, CCL2, FAM83A, and TACE, measured 24–72 hours post-injection (Won et al., 2014, DOI).
• Obese mouse models treated with ATS-9R/shFABP4 demonstrated metabolic improvement and >20% reduction in body weight over 4 weeks (Won et al., 2014, DOI).
• ATS-9R complexes display low cytotoxicity (cell viability >80%) and no significant hepatic or renal toxicity at working doses (APExBIO, product page).

Compared to previous work, this article provides updated quantification and safety data for ATS-9R, clarifying distinctions from traditional viral and non-targeted non-viral carriers. For additional discussion of mechanism and applications, see "ATS-9R: Targeted Non-Viral Gene Delivery to White Adipose..."; this article extends their overview by emphasizing recent in vivo benchmarks and optimized delivery ratios.

For further mechanistic insights, consult "ATS-9R: Targeted Non-Viral Gene Delivery for Adipocyte Re..."; the present article updates protocol parameters and safety endpoints.

Applications, Limits & Misconceptions

ATS-9R is primarily used for targeted gene silencing in mature adipocytes and ATMs. Applications include:

• Obesity-associated inflammation studies
• Insulin resistance amelioration research
• Gestational diabetes mellitus (GDM) animal model interventions
• Obesity-induced type 2 diabetes research

ATS-9R enables delivery of shRNA, sgRNA/Cas9, and other therapeutic nucleic acids. It is not suitable for long-term gene expression or for use in preadipocytes lacking surface Prohibitin. The specificity for white adipose tissue limits off-target effects but also precludes use in brown adipose tissue and non-adipose organs.

Common Pitfalls or Misconceptions

• Not effective in brown adipose tissue: ATS-9R does not efficiently target brown adipocytes due to lower Prohibitin surface expression.
• Not a viral vector substitute for long-term transgene expression: ATS-9R enables transient gene silencing, not stable integration.
• Not suitable for undifferentiated preadipocytes: Prohibitin is upregulated during adipocyte maturation; targeting preadipocytes yields low uptake.
• Not recommended for direct hepatic targeting: Although the liver clears the complex, hepatic gene delivery is inefficient.
• Temperature sensitivity: The peptide loses targeting efficiency at elevated temperature; always prepare fresh and store at 20C.

Workflow Integration & Parameters

In vitro, ATS-9R is typically used at 1025 bcg/ml peptide with 5 bcM2 bcg nucleic acid, in serum-free media. For animal studies, intraperitoneal injection of 0.20.35 mg/kg peptide, twice weekly, or four consecutive doses with 0.350.7 mg/kg nucleic acid, is standard. Complex formation at a 3:1 or 6:1 peptide:nucleic acid weight ratio is recommended. Nanoparticle formation and condensation efficiency should be confirmed by agarose gel retardation assay. The product is soluble in DMSO and should be stored at 20C. Clearance occurs via the liver within 1224 hours.

For a stepwise protocol and troubleshooting, refer to the C8721 kit documentation at the APExBIO product page.

For further protocol optimization, see "ATS-9R: Targeted Non-Viral Gene Delivery to White Adipose..."; this article clarifies working concentrations and in vivo dosing validated in recent studies.

Conclusion & Outlook

ATS-9R (Adipocyte-targeting sequence-9-arginine) provides a robust, non-viral solution for adipocyte-specific gene silencing in metabolic disease research. It achieves high targeting specificity and knockdown efficiency with minimal toxicity. Limitations include restriction to white adipose tissue and transient gene expression. Ongoing research aims to expand the payload capacity and extend tissue specificity. For researchers seeking an efficient, validated system for adipocyte gene manipulation, ATS-9R from APExBIO offers a leading-edge toolset.

For product availability, specifications, and MSDS, visit the ATS-9R (Adipocyte-targeting sequence-9-arginine) product page.